Last reviewed · How we verify
NCT04737811
Validation of the Turkish Swallowing Disturbance Questionnaire
trial testing Turkish Version of Swallowing Disturbance Questionnaire in Parkinson Disease in 152 participants. Completed in 7 March 2021.
7 March 2021
Quick facts
| Lead sponsor | Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 152 |
| Start date | 7 December 2020 |
| Primary completion | 7 March 2021 |
| Estimated completion | 7 March 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Turkish Version of Swallowing Disturbance Questionnaire
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Dysphagia — all drugs for Dysphagia →
Sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Who can join
Adults 18 to 80, any sex, with Parkinson Disease or Dysphagia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose of the study is the validity and reliability of the Turkish version of the Swallowing Disturbance Questionnaire (SDQ-T), so that it would be used as an assessment tool for Turkish Parkinson Disease's (PD) patients. Despite being translated and validated in many languages, there is no validated Turkish version of SDQ to measure the severity of dysphagia in PD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04737811
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization trials
Trials by the same sponsor.
- NCT07500285 — Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Ph · Phase 2 · not yet recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07390279 — Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia · recruiting
- NCT07357922 — Serum Progesterone and Threatened Abortion During Lactation · not yet recruiting
- NCT07283250 — Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04737811 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
- Last refreshed: 3 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04737811.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing